kempharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (nces) to treat serious medical conditions through its proprietary and broadly applicable ligand activated therapy (lat) approach. the company utilizes its lat technology to generate improved prodrug versions of fda approved drugs in the high needs areas of pain, adhd and other cns diseases.
Company profile
Ticker
ZVRA
Exchange
Website
CEO
Travis Mickle
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
KEMPHARM INC, KEMPHARM, INC
SEC CIK
ZVRA stock data
Latest filings (excl ownership)
8-K
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of
26 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
4 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
28 Feb 24
8-K/A
Financial Statements and Exhibits
5 Feb 24
S-3
Shelf registration
5 Feb 24
8-K
Departure of Directors or Certain Officers
23 Jan 24
8-K
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
8 Jan 24
8-K
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
27 Dec 23
424B5
Prospectus supplement for primary offering
21 Nov 23
Transcripts
ZVRA
Earnings call transcript
2023 Q3
7 Nov 23
ZVRA
Earnings call transcript
2023 Q2
14 Aug 23
ZVRA
Earnings call transcript
2023 Q1
15 May 23
ZVRA
Earnings call transcript
2022 Q4
7 Mar 23
ZVRA
Earnings call transcript
2022 Q3
10 Nov 22
ZVRA
Earnings call transcript
2022 Q3
9 Nov 22
ZVRA
Earnings call transcript
2022 Q2
11 Aug 22
ZVRA
Earnings call transcript
2022 Q2
11 Aug 22
ZVRA
Earnings call transcript
2022 Q1
13 May 22
ZVRA
Earnings call transcript
2022 Q1
12 May 22
Latest ownership filings
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
4
Joshua Schafer
2 Feb 24
4
Timothy J. Sangiovanni
2 Feb 24
4
Christal M M Mickle
2 Feb 24
4
Sven Guenther
2 Feb 24
4
R. LaDuane Clifton
2 Feb 24
4
Neil F. McFarlane
2 Feb 24
4
Alvin Shih
2 Feb 24
3
Alvin Shih
2 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 43.27 mm | 43.27 mm | 43.27 mm | 43.27 mm | 43.27 mm | 43.27 mm |
Cash burn (monthly) | 7.64 mm | 2.23 mm | 5.12 mm | 3.68 mm | 1.54 mm | 1.82 mm |
Cash used (since last report) | 45.61 mm | 13.32 mm | 30.57 mm | 21.98 mm | 9.21 mm | 10.86 mm |
Cash remaining | -2.34 mm | 29.94 mm | 12.70 mm | 21.29 mm | 34.06 mm | 32.41 mm |
Runway (months of cash) | -0.3 | 13.4 | 2.5 | 5.8 | 22.1 | 17.8 |
Institutional ownership, Q3 2023
32.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 81 |
Opened positions | 14 |
Closed positions | 6 |
Increased positions | 25 |
Reduced positions | 16 |
13F shares | Current |
---|---|
Total value | 55.85 bn |
Total shares | 11.73 mm |
Total puts | 141.00 k |
Total calls | 129.40 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Nantahala Capital Management | 2.31 mm | $11.13 bn |
BLK Blackrock | 2.15 mm | $10.37 bn |
Vanguard | 1.61 mm | $7.77 bn |
Geode Capital Management | 679.05 k | $3.27 bn |
Janney Montgomery Scott | 674.37 k | $3.25 mm |
STT State Street | 628.23 k | $3.03 bn |
Auctus Fund | 450.00 k | $4.25 mm |
Retirement Planning Co of New England | 347.40 k | $1.67 bn |
Braun Samuel J | 323.50 k | $2.83 mm |
NTRS Northern Trust | 270.44 k | $1.30 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jan 24 | Sangiovanni Timothy J. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 35,000 | 0.00 | 35,000 |
31 Jan 24 | Christal M M Mickle | RSU Common Stock | Grant | Acquire A | No | No | 0 | 77,000 | 0.00 | 77,000 |
31 Jan 24 | Sven Guenther | RSU Common Stock | Grant | Acquire A | No | No | 0 | 79,000 | 0.00 | 79,000 |
31 Jan 24 | Clifton R. LaDuane | RSU Common Stock | Grant | Acquire A | No | No | 0 | 130,000 | 0.00 | 130,000 |
31 Jan 24 | McFarlane Neil F. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 700,000 | 0.00 | 700,000 |
News
Zevra Therapeutics: Q4 Earnings Insights
28 Mar 24
Zevra Therapeutics Q4 2023 GAAP EPS $(0.40) Misses $(0.27) Estimate, Sales $13.217M Beat $11.738M Estimate
28 Mar 24
Earnings Scheduled For March 28, 2024
28 Mar 24
Earnings Outlook For Zevra Therapeutics
27 Mar 24
Zevra Therapeutics Reports Data From Phase 2 Clinical Trial Of KP1077 For Idiopathic Hypersomnia; Says KP1077 Demonstrates Clinically Meaningful Benefits For Key IH Symptoms
26 Mar 24
Press releases
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
28 Mar 24
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
26 Mar 24
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
25 Mar 24
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024
18 Mar 24
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
4 Mar 24